Wockhardt Q1 FY25 revenue up 14%
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Decision on EU marketing authorisation for this population expected by September 2024
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Subscribe To Our Newsletter & Stay Updated